Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 10/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23806998 | 0.84 | CARM1 (0.56) | BCHESMN1; SMN2ALDH1A1MEN1POLB | |
| SCHEMBL21997939 | 0.84 | SMN1; SMN2 (0.60) | BCHESMN1; SMN2MEN1KMT2ACYP2C19 | |
| SCHEMBL27278124 | 0.79 | SMN1; SMN2 (0.48) | BCHESMN1; SMN2ALDH1A1MEN1POLB | |
| SCHEMBL16900141 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL16228724 | 0.78 | NPC1 (0.53) | SMN1; SMN2ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL24251635 | 0.77 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL23946138 | 0.77 | SMN1; SMN2 (0.43) | BCHESMN1; SMN2ALDH1A1MEN1POLB | |
| SCHEMBL21128474 | 0.76 | SMN1; SMN2 (0.50) | BCHESMN1; SMN2ALDH1A1MEN1POLB | |
| SCHEMBL20981267 | 0.76 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL18799328 | 0.76 | HTT (0.59) | SMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | BCHE 2634/4885SMN1; SMN2 2647/4885ALDH1A1 2776/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | BCHE 2634/4885SMN1; SMN2 2647/4885ALDH1A1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.